- Bryant D. Lim appointed as General Counsel and Secretary of the Board of Directors -
- Chief Financial Officer Louis J. Arcudi III departing the company related to company consolidation to
Pennsylvania -
EXTON, Pa., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on
the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today
announced several organization updates. The company has appointed Bryant D. Lim as Senior Vice President, General Counsel and
Secretary of the Board of Directors.
Mr. Lim most recently served as Vice President, Assistant General Counsel of Incyte Corporation. Prior to Incyte, Mr. Lim
held roles of increasing responsibility at ViroPharma Incorporated, Merck & Co., Inc. and Morgan, Lewis & Bockius, LLP. Mr.
Lim began his legal career as a law clerk for a federal judge. Mr. Lim received his J.D. from Villanova University School of
Law, where he serves on its adjunct faculty. Mr. Lim received his Bachelor of Arts from University of Rochester.
“Bryant’s experiences with Incyte will be incredibly valuable to us as we advance tilsotolimod. Bryant also played an
integral role in helping to shape the legal landscape at ViroPharma as the company matured into a commercial entity and I am
thrilled to be working together with him again as Idera advances towards becoming a commercial organization,” stated Vincent
Milano, Idera’s Chief Executive Officer.
“It is an exciting time in the field of immuno-oncology and equally exciting time to be joining Idera to take part in the
development of tilsotolimod,” stated Bryant Lim, Idera’s General Counsel. “I’m also looking forward to working together again
with Vin and the team as we drive Idera towards commercialization of tilsotolimod.”
The company also announced the planned departure of Chief Financial Officer, Louis J. Arcudi III as a result of the company’s
recently announced consolidation to Exton, PA headquarters. Mr. Arcudi joined Idera in 2007 and during his tenure, played an
instrumental role in continuing to move Idera forward including several business development deals as well as capital financings
and Idera’s initial listing on the NASDAQ market. The company expects that Mr. Arcudi will continue to serve as Chief
Financial Officer through October 31, 2018 and that Mr. Arcudi will serve as an advisor to the company through a consulting
agreement after that time.
Continued Milano, “Although it is personally disappointing to me that Lou will no longer be with us on a day-to-day basis as a
result of our decision to consolidate all of our operations in Pennsylvania; I am incredibly grateful for all he has done during
his tenure to continue to move Idera forward, often during challenging circumstances and often well beyond the typical functions of
a Chief Financial Officer.”
“I will sincerely miss my Idera family of the past 11 years,” stated Louis J. Arcudi, III. “I am a very strong believer in
tilsotolimod and the team developing this drug and I look forward to seeing the positive impact that it will have on the lives of
patients both in melanoma and beyond.”
Mr. John Kirby, Idera’s Vice President of Finance and previously its Vice President of Accounting, will assume leadership of
Idera’s Finance function upon Mr. Arcudi’s departure. Mr. Kirby has been with Idera since 2015 and previously held positions
of increasing responsibility at Endo Pharmaceuticals, ViroPharma Incorporated, Astra Zeneca, and KPMG.
About Idera Pharmaceuticals
Harnessing the approach of the earliest researchers in immunotherapy and Idera’s experience in developing proprietary immunology
technologies, Idera’s lead development program is focused on priming the immune system to play a more powerful role in fighting
cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera is committed to working with
investigators and partners who share the common goal of addressing the unmet needs of patients suffering from difficult to treat,
unmet cancers. To learn more about Idera, visit www.iderapharma.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact,
included or incorporated in this press release are forward-looking statements. The words “believes,” “anticipates,” “estimates,”
“plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “continue,” “will,” and “would” and
similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these
identifying words. Idera cannot guarantee that it will actually achieve the plans, intentions or expectations disclosed in its
forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements. There are a number
of important factors that could cause Idera’s actual results to differ materially from those indicated or implied by its
forward-looking statements, including those important factors set forth under the caption “Risk Factors” in the Company’s Annual
Report on Form 10-K for the period ended December 31, 2017. Although Idera may elect to do so at some point in the future, the
Company does not assume any obligation to update any forward-looking statements and it disclaims any intention or obligation to
update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor and Media Contact
Robert Doody
Vice President, Investor Relations and Corporate Communications
Office: 484-348-1677
rdoody@iderapharma.com
